Kiromic BioPharma (NASDAQ:KRBP) Shares Down 7.1% – What’s Next?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) was down 7.1% during trading on Monday . The company traded as low as $1.50 and last traded at $1.50. Approximately 1,395 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 2,604 shares. The stock had previously closed at $1.62.

Kiromic BioPharma Trading Down 7.1 %

The stock has a market capitalization of $2.30 million, a price-to-earnings ratio of -0.43 and a beta of 1.84. The stock’s 50 day moving average is $1.08 and its 200 day moving average is $1.26.

Kiromic BioPharma Company Profile

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.